e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Treatment of tuberculosis and adverse drug reactions
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
M. Ralli, L. Stournara, E. G. Tsaroucha, M. Palavra, S. Karagiannis, V. Sgountzos, A. Papavassiliou (Athens, Greece)
Source:
Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Session:
Treatment of tuberculosis and adverse drug reactions
Session type:
Thematic Poster Session
Number:
4398
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Ralli, L. Stournara, E. G. Tsaroucha, M. Palavra, S. Karagiannis, V. Sgountzos, A. Papavassiliou (Athens, Greece). Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM). Eur Respir J 2011; 38: Suppl. 55, 4398
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009
Surgical treatment of multidrug resistant pulmonary tuberculosis (MDR-TB)
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Surgical treatment of multidrug-resistant tuberculosis (MDR TB)
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Year: 2003
Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB)
Source: Eur Respir J 2005; 26: Suppl. 49, 199s
Year: 2005
Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR)
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012
Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT)
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013
Artificial pneumothorax in the treatment of multi drug resistant tuberculosis (MDR TB)
Source: Eur Respir J 2006; 28: Suppl. 50, 586s
Year: 2006
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB.
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran
Source: Eur Respir J 2004; 24: Suppl. 48, 657s
Year: 2004
Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB)
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept